Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 7/20 | 0.39 |
| ▸ | STAT6 | P42226 | 3/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.38 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.38 |
| ▸ | FAP | Q12884 | 3/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.38 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.33 |
| ▸ | PITRM1 | Q5JRX3 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22525831 | 1.00 | DPP4 (0.39) | DPP4STAT6DPP8DPP9FAP | |
| SCHEMBL8088388 | 0.87 | DPP4 (0.40) | DPP4STAT6DPP8DPP9FAP | |
| SCHEMBL23959050 | 0.87 | DPP4 (0.37) | DPP4STAT6DPP8DPP9FAP | |
| SCHEMBL21696763 | 0.86 | STAT6 (0.43) | DPP4STAT6DPP8DPP9FAP | |
| SCHEMBL25885362 | 0.86 | STAT6 (0.43) | DPP4STAT6DPP8DPP9FAP | |
| SCHEMBL26749977 | 0.85 | DPP4 (0.35) | DPP4STAT6DPP8DPP9FAP | |
| SCHEMBL26749959 | 0.83 | STAT6 (0.38) | DPP4STAT6DPP8DPP9FAP | |
| SCHEMBL26751293 | 0.83 | STAT6 (0.36) | DPP4STAT6DPP8DPP9FAP | |
| SCHEMBL12811967 | 0.82 | STAT6 (0.38) | DPP4STAT6DPP8DPP9FAP | |
| SCHEMBL8253773 | 0.81 | ELANE (0.41) | STAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | DPP4 1068/4885STAT6 4544/4885DPP8 831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.